The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19) : A Position Paper by Four Medical Societies from Greece
© The Author(s) 2021..
In light of the accumulating evidence for survival benefit coming from the use of macrolides for community-acquired pneumonia (CAP), a group of experts from the field of internal medicine and infectious diseases frame a position statement on the use of macrolides for the management of bacterial CAP and for infection by the novel coronavirus (COVID-19). The statement is framed taking into consideration existing publications and own research experience. The main content of this statement is that the combination of one β-lactam and a macrolide should be the first treatment of choice for patients with severe bacterial CAP. Severity is assessed as scoring 2 or more points on the CURB65 scoring system of severity or as pneumonia severity index III to V or C-reactive protein more than 150 mg/l; the suggested macrolide is either azithromycin or clarithromycin. The experts also suggest that in COVID-19 pneumonia, the combination of one β-lactam and a macrolide should be reserved only when there is strong suspicion of bacterial co-infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
Infectious diseases and therapy - (2021) vom: 16. Juni, Seite 1-15 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Giamarellos-Bourboulis, Evangelos J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Azithromycin |
|---|
| Anmerkungen: |
Date Revised 22.02.2024 published: Print-Electronic figshare: 10.6084/m9.figshare.14672379 Citation Status Publisher |
|---|
| doi: |
10.1007/s40121-021-00471-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32702867X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32702867X | ||
| 003 | DE-627 | ||
| 005 | 20240229143522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40121-021-00471-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM32702867X | ||
| 035 | |a (NLM)34155472 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Giamarellos-Bourboulis, Evangelos J |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19) |b A Position Paper by Four Medical Societies from Greece |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a figshare: 10.6084/m9.figshare.14672379 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2021. | ||
| 520 | |a In light of the accumulating evidence for survival benefit coming from the use of macrolides for community-acquired pneumonia (CAP), a group of experts from the field of internal medicine and infectious diseases frame a position statement on the use of macrolides for the management of bacterial CAP and for infection by the novel coronavirus (COVID-19). The statement is framed taking into consideration existing publications and own research experience. The main content of this statement is that the combination of one β-lactam and a macrolide should be the first treatment of choice for patients with severe bacterial CAP. Severity is assessed as scoring 2 or more points on the CURB65 scoring system of severity or as pneumonia severity index III to V or C-reactive protein more than 150 mg/l; the suggested macrolide is either azithromycin or clarithromycin. The experts also suggest that in COVID-19 pneumonia, the combination of one β-lactam and a macrolide should be reserved only when there is strong suspicion of bacterial co-infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Azithromycin | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clarithromycin | |
| 650 | 4 | |a Community-acquired pneumonia | |
| 650 | 4 | |a Immunomodulation | |
| 700 | 1 | |a Daikos, George L |e verfasserin |4 aut | |
| 700 | 1 | |a Gargalianos, Panagiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Gogos, Charalambos |e verfasserin |4 aut | |
| 700 | 1 | |a Lazanas, Marios |e verfasserin |4 aut | |
| 700 | 1 | |a Panagopoulos, Periklis |e verfasserin |4 aut | |
| 700 | 1 | |a Poulakou, Garyphallia |e verfasserin |4 aut | |
| 700 | 1 | |a Sambatakou, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Samarkos, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d 2012 |g (2021) vom: 16. Juni, Seite 1-15 |w (DE-627)NLM240483693 |x 2193-8229 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:16 |g month:06 |g pages:1-15 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40121-021-00471-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 16 |c 06 |h 1-15 | ||